Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS)
The Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS) is made up of an esteemed group of health economists and policy researchers from major institutions across the globe who have been at the forefront of the incorporation of genomics into clinical care. The working group is chaired by Kathryn A. Phillips, PhD, Director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) at UCSF. GEECS members include:
|James Buchanan, DPhil||University of Oxford||Oxford, United Kingdom|
|Kurt Christensen, PhD||Brigham and Women’s Hospital and Harvard Medical School||Boston, MA, USA|
|American Institutes for Research||Chapel Hill, NC, USA|
|Deborah Marshall, PhD||University of Calgary||Calgary, Alberta, Canada|
|University of California, San Francisco||San Francisco, CA, USA|
|Dean Regier, PhD||University of British Columbia||Vancouver, British Columbia, Canada|
|Sarah Wordsworth, PhD||University of Oxford||Oxford, United Kingdom|
Recently, the Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS) published a special theme section of the September 2018 issue of Value in Health specifically focuses on assessing the value of NGS-based clinical testing. While it’s critical to assess the value of NGS, there are many methodological challenges to doing so. This series of expert articles push the envelope by not only highlighting the challenges, but by suggesting innovative solutions to move the value assessment process forward for precision medicine. The papers incorporate a wide range of perspectives and topics and use both systematic reviews and case studies – but they all focus on the overarching issue of proposing new methodologies to assess the value of NGS-based technologies in clinical care. The proposals included are not intended only for health economic researchers, but also to other stakeholders including health technology assessment organizations, payers, clinical researchers, and the biotechnology and pharmaceutical industries.
Value in Health theme section articles
- Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042.
- Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using ‘big’ data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053.
- Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of Health and Non-health Benefits from Next Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047.
- Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. 2018; 21(9):1054-1061.
- Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062-1068.